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Abstract
Real-Time Quaking-Induced Conversion (RT-QuIC) testing of human cere-
brospinal fluid (CSF) is highly sensitive and specific in discriminating sporadic
CJD patients from those without prion disease. Here, using CSF samples from
113 CJD and 64 non-prion disease patients, we provide the first direct and con-
current comparison of our improved RT-QuIC assay to our previous assay,
which is similar to those commonly used internationally for CJD diagnosis.
This extended comparison demonstrated a ~21% increase in diagnostic sensitiv-
ity, a 2-day reduction in average detection time, and 100% specificity.
Creutzfeldt-Jakob disease (CJD) is a human prion disease
occurring with sporadic, genetic, or infectious etiologies.
The agents responsible for these diseases are prions, which
are altered forms of the ubiquitously and normally
expressed prion protein (PrP). The most common form
of prion disease in humans is sporadic CJD (sCJD), char-
acterized by a spectrum of variable clinical signs evolving
over a period of weeks to months. Early and accurate
diagnosis has been a long standing difficulty, currently
relying heavily on combinations of clinical features,
specifically MRI and EEG changes, and the detection of
surrogate markers such as the 14-3-3 protein in CSF.1
Such criteria can yield diagnoses of probable or possible
sCJD, however, according to current international
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guidelines, definite diagnosis requires the detection of
pathological prion protein (PrPCJD) in the central nervous
system tissue. Because the acquisition of such tissue
requires brain biopsies2 or autopsies, most definitive diag-
noses are made postmortem.
The Real-Time Quaking-Induced Conversion (RT-
QuIC) and the amyloid seeding (ASA) assays exploit the
ability of PrPCJD to seed the polymerization of protease
sensitive recombinant PrP (rPrPsen) into amyloid fibrils
detectable by thioflavin-T (ThT) fluorescence.3–5 This test
allows for rapid, sensitive, and quantitative detection of
prion-associated seeds in a variety of biological tissues and
fluids.6–14
Recently the RT-QuIC has been used for sensitive and
specific detection of PrPCJD in human cerebrospinal
fluid5,15–19 which is much easier than brain tissue to obtain
from live patients. Numerous laboratories have imple-
mented and extensively assessed the use of RT-QuIC anal-
ysis of CSF for intra vitam diagnosis of CJD using hamster
or human rPrPsen with amino acids 23–231 as the sub-
strate, no detergents, and 37 or 42°C incubations.13–18
These assays require 2.5–5 days and miss 11–23% of CJD
cases. We call our version of this generation of the assay
PQ-CSF, for previous RT-QuIC for CSF.19 However, we
recently described an improved, second generation RT-
QuIC for CSF (IQ-CSF) assay which uses a truncated form
of hamster rPrPSen (amino acids 90–231) as a substrate,
55°C incubations, and the addition of 0.002% sodium
dodecyl sulfate (SDS). Our initial evaluation of the IQ-CSF
assay indicated enhanced fluorescence responses to sCJD
seeds, greater analytical and diagnostic sensitivity, and
markedly shorter testing times of ~4–24 h.19
For this study, we analyzed a new and larger panel of
CJD patients and, for the first time, directly compared
the performance of the PQ- and IQ-CSF conditions when
tested simultaneously on the same specimens. CSF sam-
ples were gathered at multiple locations in Italy including
the University of Verona (Verona), Ospedale Maria Vitto-
ria (Torino), and Istituto Superiore di Sanita (Rome). All
of the 177 CSF samples, 113 CJD, and 64 non-prion dis-
ease patients were tested blindly. Final diagnosis of the
prion disease patients revealed 36 definite, 68 probable,
three genetic CJD (including one E200K, and two V210I)
cases, and one P102L Gerstmann-Straussler-Scheinker
(GSS) syndrome case. Table S1 shows the demographic
and clinical information for each prion disease patient, as
well as 14-3-3 and tau measures when available. Direct
comparative analysis of each sample using PQ- and IQ-
CSF RT-QuIC conditions was done within the same exper-
iment, using the same solutions and materials. Non-prion
disease control patients included 21 males and 43 females
with an average age of 65  18 years (mean  SD).
Eighteen patients had diagnoses of non-neurological
disease and 46 patients had non-prion neurological dis-
eases including: amyotrophic lateral sclerosis (n = 3),
Alzheimer’s disease (n = 3), chronic inflammatory
demyelinating polyneuropathy (n = 1), cognitive decline
(n = 13), dystonia (n = 1), frontotemporal dementia
(n = 9), lewy body dementia (n = 1), mild cognitive
impairment (n = 4), multiple system atrophy (n = 1),
Parkinsonism (n = 1), and rapidly progressive dementia
(n = 9).
Figure 1A shows the comparison of the average RT-
QuIC amplification kinetics for CJD and non-prion dis-
ease CSF using PQ- or IQ-CSF assays. Using PQ-CSF and
our previously established criteria for signal thresholds
and time cutoffs6,19, a majority of samples scored positive
after 47 h and full analysis typically required at least 90 h
(Fig. 1A and B). ThT fluorescence amplitudes averaged
26% of our maximum reading capacity with only 16% of
the samples registering above 50% (Fig. 1C). The same
samples tested on the same day by IQ-CSF RT-QuIC
showed significantly stronger fluorescence readings
(Fig. 1A and Table 1) and faster amplification kinetics
(Fig 1B, P < 0.0001, Mann–Whitney test) with the major-
ity of positives being detected within 10 h and assay con-
cluded within 24 h (Fig. 1A and B). IQ-CSF conditions
averaged 85% of our maximum reading capacity with
84% of the readings being greater than 50% and 68% of
all samples reading 100% (Fig. 1A and C). The median
percent maximum ThT readings for PQ and IQ-CSF
conditions were 22 and 100%, respectively.
We calculated our ThT fluorescence threshold for a
reaction to be considered positive based on the mean
ThT value of all negative control samples at 90 h for PQ-
CSF, or 24 h for IQ-CSF, plus 10 standard devia-
tions6,19,20. This generated thresholds of ~2 and ~6% of
saturating fluorescence for PQ-CSF and IQ-CSF, respec-
tively. In addition, as has been common in previous stud-
ies6,19, because of the rare occurrence of single wells
exceeding the threshold in non-prion disease controls
within the cutoff time of the reaction, at least two of four
replicate reactions had to each exceed the threshold for a
sample to be considered overall positive. Since these cut-
offs are based on the signal to noise ratio of the negative
control samples, careful consideration was given to the
designated cutoff value in order to maximize sensitivity
without compromising specificity. Although the specificity
for both protocols was 100% (CI: 93–100%), under PQ-
CSF conditions only 82 out of the 113 CJD samples tested
positive (Table 1), leading to a 73% (95% CI: 63–80%)
sensitivity. The same sample set analyzed by IQ-CSF
resulted in 106 positive specimens out of 113 tested, giv-
ing a 94% (CI: 87–97%) sensitivity. Sensitivities by IQ-
CSF for probable and definite CJD diagnoses were 97%
and 92%, respectively. Furthermore, MM, MV, and VV
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polymorphisms at codon 129 had sensitivities by IQ-CSF
of 98, 96, and 90%, respectively. None of the non-prion
disease patients’ samples showed fluorescence that
exceeded the designated threshold. Maximum ThT fluo-
rescence values for non-prion disease patients were under
0.9% and 3.0% of saturation for PQ- and IQ-CSF, respec-
tively. PQ-CSF conditions produced an average maximum
ThT fluorescence of 0.4  0.2% (mean  SD) with a
median of 0.4% while IQ-CSF conditions produced an
average of 1.2  0.5% (mean  SD) with a median of
1.0%.
A comparison (Fig. 1B) of the time to threshold
(hours) of the 82 positive PQ-CSF versus the 106 positive
IQ-CSF samples further illustrates how much faster IQ-
CSF kinetics are compared to PQ-CSF. Figure 1C shows
the peak fluorescence values from the average of four
replicate wells for each sample for PQ- and IQ-CSF tests
(Fig. 1C and Table 1). The baselines were subtracted
from the data of the averaged individual samples and
normalized to the saturating ThT fluorescence level of
the plate reader (as described previously6,19). These
results illustrate that IQ-CSF allowed significantly stron-
ger discrimination between CJD-positive and non-prion
disease control CSF samples. Although IQ-CSF did not
detect seeding activity in all of the 113 CJD patients
(Table 1, see patients 1, 34, 92, 98, and 106–108), it was
positive for all of those who were positive by PQ-CSF as
well as 24 additional patients who were negative by PQ-
CSF (Table 1, blue shading). When the sample codes
were broken, we discovered that duplicate aliquots from
five patients had been tested within the panels as replica-
tion controls. The duplicate aliquots from the same
patients were consistently positive with IQ-CSF but were
not as consistent in the PQ-CSF analyses (Table 1,
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Figure 1. Faster and more sensitive detection of prion seeding
activity in CSF from CJD patients by IQ-CSF testing. (A) Mean ThT
fluorescence of RT-QuIC reactions seeded with CSF from non-prion
disease controls using PQ-CSF (green) and IQ-CSF (orange) or from
CJD patients using PQ-CSF (blue) and IQ-CSF (red) are shown.
Traces denote the mean  SD of all biological replicates (n = 113
CJD and n = 64 non-prion disease) from each category as indicated
by the legend. Each biological replicate was in turn an average
from four technical replicate wells. (B) Comparison of the time for
each CJD sample to cross the designated positivity threshold for
PQ-CSF (blue circles, n = 82) and IQ-CSF (red squares, n = 106).
Samples that did not cross the threshold were excluded from this
analysis and are not plotted. Each point is displayed as the mean
of four technical replicates. Mean  SD of the groups are
displayed as the solid horizontal line and the vertical error bars,
respectively. The large dashed line is the 90-h time cutoff used for
PQ-CSF and the small dotted line is the 24-h time cutoff used for
IQ-CSF. (C) End point values for PQ-CSF or 24-h maximum ThT
fluorescence values for IQ-CSF tests for each biological replicate
displayed as the mean of four technical replicates. The average
fluorescence value from all 113 CJD patients tested blinded using
PQ-CSF (blue circles) or IQ-CSF (red squares) and 64 non-prion
disease patients tested blinded using PQ-CSF (green circles) or IQ-
CSF (orange squares) conditions is shown for each individual
sample with mean (horizontal line) and SD (vertical lines). Long and
short dashed lines indicate the ThT fluorescence positivity thresholds
calculated to be ~2 and ~6% for PQ-CSF and IQ-CSF, respectively
[mean value at the time of assessment from all negative control
samples plus 10 standard deviations6,19]. P values were calculated
using the Mann–Whitney test.
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patients: 62 and 90, 63 and 64, 66 and 70, 68 and 91,
and 71 and 86). Additionally, all of the seven CJD
patients who were negative by IQ-CSF were also negative
by PQ-CSF (Table 1, yellow shading), suggesting that
prion seeding activity in these samples was below the
detection limit of both assays.
Overall, this faster and more sensitive IQ-CSF assay
provided a ~21% increase in diagnostic sensitivity and a
~42-h reduction in average detection time for positive
samples, while maintaining 100% diagnostic specificity. A
much larger sample size tested across multiple laborato-
ries will be required to fully validate these new IQ-CSF
Table 1. RT-QuIC percent maximum ThT fluorescence following PQ- or IQ-CSF analysis for 113 CJD CSF samples.
Percent (%) maximum ThT fluorescence
Patient PQ-CSF IQ-CSF Patient PQ-CSF IQ-CSF Patient PQ-CSF IQ-CSF
1 0.9 0.5 39 16.7 100.0 77 67.7 100.0
2 32.4 100.0 40 9.9 99.4 78 0.2 23.7
3 42.3 100.0 41 21.9 100.0 79 45.8 100.0
4 19.6 100.0 42 32.5 100.0 80 53.6 100.0
5 38.2 100.0 43 0.9 91.0 81 15.0 50.5
6 45.0 100.0 44 43.5 100.0 82 28.4 100.0
7 31.5 100.0 45 17.1 100.0 83 28.4 99.9
8 39.0 100.0 46 11.0 100.0 84 50.5 100.0
9 20.9 75.0 47 0.4 98.4 85 92.1 100.0
10 33.3 100.0 48 26.0 100.0 86 14.2 74.8
11 36.6 100.0 49 4.71 47.1 87 0.6 100.0
12 2.3 46.4 50 27.7 100.0 88 13.0 100.0
13 40.0 100.0 51 28.1 100.0 89 45.4 100.0
14 26.2 100.0 52 30.3 100.0 90 9.21 100.0
15 47.7 100.0 53 14.8 100.0 91 30.7 100.0
16 31.9 100.0 54 22.0 100.0 92 0.5 3.0
17 71.4 100.0 55 0.8 94.4 93 46.8 100.0
18 76.8 100.0 56 5.71 49.8 94 0.8 49.7
19 32.0 100.0 57 13.8 49.5 95 0.3 49.6
20 4.5 100.0 58 38.0 100.0 96 61.5 100.0
21 9.5 100.0 59 30.0 100.0 97 62.6 100.0
22 52.8 100.0 60 8.8 100.0 98 0.2 4.4
23 21.8 99.9 61 24.0 100.0 99 39.4 100.0
24 20.1 100.0 62 16.9 100.0 100 0.0 100.0
25 0.2 10.5 63 0.1 42.0 101 17.6 100.0
26 25.2 100.0 64 42.0 100.0 102 0.2 100.0
27 0.1 67.5 65 9.21 61.8 103 12.1 100.0
28 9.41 100.0 66 9.21 74.2 104 62.1 100.0
29 53.0 100.0 67 0.1 34.3 105 22.4 100.0
30 0.0 74.7 68 79.9 100.0 106 0.1 2.8
31 0.1 49.7 69 0.1 89.2 107 0.0 4.7
32 21.8 75.0 70 43.0 100.0 108 6.41 5.9
33 4.5 100.0 71 8.8 100.0 109 10.6 75.4
34 0.1 2.0 72 72.5 100.0 110 37.2 100.0
35 0.2 94.9 73 40.8 100.0 111 14.4 100.0
36 50.1 100.0 74 58.1 100.0 112 83.5 100.0
37 52.9 100.0 75 30.9 92.9 113 6.31 60.2
38 33.0 100.0 76 77.8 100.0
These values indicate the normalized ThT response (described in6,19) for each patient at the determined cutoff time (90 h end point for
PQ-CSF and peak value within 24 h for IQ-CSF conditions). Samples scored positive (orange) when the response was above the
calculated threshold. Samples that were negative under only one condition are marked in blue, while sample that were negative under both
conditions are marked in yellow. None of the non-prion disease patients’ samples crossed threshold with ThT fluorescence values ranging
from 0 to 0.9 or 3.0 for PQ- and IQ-CSF, respectively. The following sub-set of CJD samples have been previously analyzed: one CJD patient
tested by IQ-CSF, seven by PQ-CSF, and two by both PQ- and IQ-CSF21; Sixteen non-prion disease patients were previously tested either by
PQ-CSF6 or 18 were tested by IQ-CSF.19 Here we reassayed all of these samples using both PQ- and IQ-CSF within the same experimental
setup.
1Only one of four wells crossed threshold and is therefore not considered a positive.
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conditions; however, our direct comparison confirms that
IQ-CSF allows for considerably faster and more sensitive
detection of PrPCJD seeding activity in CSF samples from
CJD patients. Therefore, with many diagnostic laborato-
ries around the world already implementing PQ-like
RT-QuIC analysis of CSF, we expect that the diagnostic
criteria for sCJD will soon be revised to include direct
detection of PrPCJD in CSF, or olfactory mucosal
samples6, by assays such as RT-QuIC. In clinical practice,
IQ-CSF testing, more so than PQ-CSF testing, should
have the ability to confirm CJD diagnoses or rapidly
divert diagnoses to potentially treatable conditions,
providing better outcomes for patients.
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Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Table S1. Patient Demographic information. Yellow
shading indicates patients who tested negative by both
PQ- and IQ-CSF conditions.
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